No Data
Warner Pharmaceutical's centralized procurement plans to win bids for three products, and the proposed bid price for Silver Blade is at a high level compared to similar categories.
① Warner Pharmaceutical's Ginkgo Biloba Blade has been selected for the national Chinese Patent Medicine procurement alliance centralized purchasing (first batch expansion continuation), with the proposed winning price being high for the same category; ② In addition to the price, the final allocation of the procurement volume is also influenced by factors such as the recognition of Medical Institutions, the supply capability of enterprises, and the quality and safety of the products.
Hunan Warrant Pharmaceutical's Three Products Shortlisted for Inclusion in China's Drug Procurement Programs
Warner Pharmaceutical (688799.SH) intends to bid for centralized procurement of some Pharmaceutical products.
Warner Pharmaceuticals (688799.SH) announced that recently, the company participated in the national Chinese Patent Medicine unified procurement office...
Warner Pharmaceuticals (688799.SH): The Active Pharmaceutical Ingredient of its subsidiary has received the approval notice for its listing application.
On December 23, Gelonghui announced that Warner Pharmaceutical (688799.SH) disclosed that its wholly-owned subsidiary Hunan Warner Large Pharmaceutical Co., Ltd. received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for Diquafosol Sodium and Methoxamine Tartrate, and the information was publicized on the "Raw Materials, Pharmaceutical Excipients and Packaging Materials Registration Information Publicity" platform of the CDE. Diquafosol Sodium is a P2Y2 receptor agonist. Diquafosol Sodium is a dinucleotide derivative that acts on conjunctival tissues and the membranes of goblet cells via the P2Y2 receptor, affecting intracellular activities.
Warner Pharmaceutical (688799.SH): Huang Bendong elected as Director.
On December 20, Gelonghui announced that Warner Pharmaceuticals (688799.SH) has elected the members of its fourth Board of Directors at the third extraordinary Shareholders' Meeting of 2024. In accordance with the relevant provisions of the Company Law, Articles of Association, and other laws and regulations, the fourth Board of Directors of the company approved the election of Mr. Huang Bendong as the Chairman of the fourth Board of Directors, with a term starting from the date of approval at this meeting until the end of the term of the fourth Board of Directors.
Hunan Warrant Pharma Completes Phase 2 Trial for Respiratory Traditional Chinese Drug
Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Shares Bounce 43% But Its Business Still Trails The Market
